126 related articles for article (PubMed ID: 37142449)
21. Influence of baseline arterial stiffness on effects of intensive compared with standard blood pressure control: a post hoc analysis of the STEP trial.
Song Q; Ling Q; Bai J; Zhang H; Bu P; Chen F; Wu S; Zhang W; Chen M; Cai J
BMC Med; 2022 Oct; 20(1):358. PubMed ID: 36261812
[TBL] [Abstract][Full Text] [Related]
22. Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials.
Li C; Chen K; Shi G; Shi R; Wu Z; Yuan X; Watson V; Jiang Z; Mai H; Yang T; Wang D; Chen T
BMC Med; 2022 Jun; 20(1):208. PubMed ID: 35718771
[TBL] [Abstract][Full Text] [Related]
23. Impact of cumulative SBP and serious adverse events on efficacy of intensive blood pressure treatment: a randomized clinical trial.
Rueda-Ochoa OL; Rojas LZ; Ahmad S; van Duijn CM; Ikram MA; Deckers JW; Franco OH; Rizopoulos D; Kavousi M
J Hypertens; 2019 May; 37(5):1058-1069. PubMed ID: 30444838
[TBL] [Abstract][Full Text] [Related]
24. Association of baseline serum cholesterol with benefits of intensive blood pressure control.
Wang X; Feng Y; Yang L; Zhang G; Tian X; Ling Q; Tan J; Cai J
Chin Med J (Engl); 2023 Sep; 136(17):2058-2065. PubMed ID: 37525354
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial.
Liu J; Wang B; Li Y; Yan X; Ge J; Li J
Am Heart J; 2023 Mar; 257():93-102. PubMed ID: 36493840
[TBL] [Abstract][Full Text] [Related]
26. Achieved systolic blood pressure and cardiovascular outcomes in 60-80-year-old patients: the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial.
Deng Y; Bai J; Yang X; Liu W; Guo Z; Zhang J; Huang R; Yang X; Yu C; Yu J; Guo X; Wu H; Liu P; Zhang W; Cai J
Eur J Prev Cardiol; 2023 Aug; 30(10):1017-1027. PubMed ID: 37172116
[TBL] [Abstract][Full Text] [Related]
27. Effect of intensive lowering of systolic blood pressure treatment on heart failure events: a meta-analysis of randomized controlled studies.
Zhang Y; Liang M; Sun C; Qu G; Shi T; Min M; Wu Y; Sun Y
J Hum Hypertens; 2019 Sep; 33(9):648-657. PubMed ID: 31363149
[TBL] [Abstract][Full Text] [Related]
28. Association of serum uric acid with benefits of intensive blood pressure control.
Wang XQ; Tan JS; Zhang SY; Zhang WL; Cai J
Rev Esp Cardiol (Engl Ed); 2023 Aug; 76(8):635-644. PubMed ID: 36716991
[TBL] [Abstract][Full Text] [Related]
29. Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial.
Deng Y; Liu W; Yang X; Guo Z; Zhang J; Huang R; Yang X; Yu C; Yu J; Cai J;
Hypertension; 2023 Sep; 80(9):1834-1842. PubMed ID: 37259845
[TBL] [Abstract][Full Text] [Related]
30. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
Lancet Diabetes Endocrinol; 2022 Sep; 10(9):645-654. PubMed ID: 35878651
[TBL] [Abstract][Full Text] [Related]
31. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
Oikonomou EK; Spatz ES; Suchard MA; Khera R
Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
[TBL] [Abstract][Full Text] [Related]
32. Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort.
Dungan K; Craven TE; Soe K; Wright JT; Basile J; Haley WE; Kressin NR; Rani U; Tamariz L; Whittle J; Wiggers A; Osei K
Diabetes Obes Metab; 2018 Mar; 20(3):629-637. PubMed ID: 29024310
[TBL] [Abstract][Full Text] [Related]
33. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
Xie X; Atkins E; Lv J; Bennett A; Neal B; Ninomiya T; Woodward M; MacMahon S; Turnbull F; Hillis GS; Chalmers J; Mant J; Salam A; Rahimi K; Perkovic V; Rodgers A
Lancet; 2016 Jan; 387(10017):435-43. PubMed ID: 26559744
[TBL] [Abstract][Full Text] [Related]
34. Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial.
Foy CG; Lovato LC; Vitolins MZ; Bates JT; Campbell R; Cushman WC; Glasser SP; Gillespie A; Kostis WJ; Krousel-Wood M; Muhlestein JB; Oparil S; Osei K; Pisoni R; Segal MS; Wiggers A; Johnson KC;
J Hypertens; 2018 Apr; 36(4):904-915. PubMed ID: 29493562
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial.
Still CH; Rodriguez CJ; Wright JT; Craven TE; Bress AP; Chertow GM; Whelton PK; Whittle JC; Freedman BI; Johnson KC; Foy CG; He J; Kostis JB; Lash JP; Pedley CF; Pisoni R; Powell JR; Wall BM;
Am J Hypertens; 2017 Dec; 31(1):97-107. PubMed ID: 28985268
[TBL] [Abstract][Full Text] [Related]
36. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
Attar A; Sayadi M; Jannati M
Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
[TBL] [Abstract][Full Text] [Related]
37. Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease.
Chang TI; Wei G; Boucher R; Kramer H; Chertow GM; Cheung AK; Greene T; Whelton PK; Beddhu S
Kidney360; 2020 May; 1(5):368-375. PubMed ID: 35369376
[TBL] [Abstract][Full Text] [Related]
38. Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study.
Hong S; Park JH; Han K; Lee CB; Kim DS; Yu SH
J Am Heart Assoc; 2021 Nov; 10(22):e020999. PubMed ID: 34726076
[TBL] [Abstract][Full Text] [Related]
39. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
[TBL] [Abstract][Full Text] [Related]
40. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial.
Byrne C; Pareek M; Vaduganathan M; Biering-Sørensen T; Qamar A; Pandey A; Olesen TB; Olsen MH; Bhatt DL
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):356-363. PubMed ID: 31529024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
